ArticleFrontiers in public health2025

Cost-effectiveness of atezolizumab versus chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-based doublet chemotherapy.

Qiuji Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.